Shri Ahimsa Naturals Ltd

Shri Ahimsa Naturals Ltd maintains a strong liquidity position, with a current ratio of 4.01, indicating the company can cover its short-term obligations more than four times over. The company has no long-term debt, and its total liabilities are significantly lower than its total equity, suggesting a conservative capital structure. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints if short-term obligations increase. Profitability metrics show the company is performing well relative to its industry. Return on equity (ROE) of 14.17% and return on assets (ROA) of 11.35% are strong, indicating efficient use of equity and assets to generate returns. These figures are well above the typical thresholds for pharmaceutical and nutraceutical firms, suggesting robust operational performance. The company’s revenue is concentrated in a few key products, including natural caffeine, Green Coffee Bean Extract, and Ashwagandha P.E. While the company exports globally, the financial snapshot does not provide geographic revenue breakdowns, making it difficult to assess exposure to specific markets. The lack of geographic diversification could pose a risk if demand in key export regions declines. Growth trajectory appears stable, with a net income of ₹218.99 million and operating income of ₹286.68 million in the latest period. However, the outlook does not provide specific numeric deltas for future years, so it is unclear whether the company is expected to maintain or accelerate its growth. The capital expenditure of ₹-68.21 million suggests the company is not currently investing heavily in expansion, which may limit future growth unless offset by organic demand. Risk factors include the company’s reliance on a narrow product portfolio and potential regulatory changes in export markets. The risk assessment classifies liquidity as medium, and while dilution is currently low, the absence of diluted shares suggests no immediate pressure from share issuance. The company’s conservative debt structure and strong cash flow from operations provide some buffer against external shocks. Recent filings and transcripts are not provided in the input data, so no specific events can be cited. However, the company’s adherence to international pharmacopoeial standards (USP, FCC, EP, BP, IP, JP) suggests a focus on quality and regulatory compliance, which is critical for maintaining export markets.